Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serzone Labeling Change Suggests Second-Line Use; Generics Affected

Executive Summary

Labeling for generic versions of Bristol-Myers Squibb's Serzone will encourage second-line use due to an increased risk of hepatotoxicity with the antidepressant

You may also be interested in...



Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out

Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request

Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?

Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14

Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk

Bristol-Myers Squibb's Serzone offers "no unique therapeutic benefit" to justify continued marketing in light of liver toxicity concerns, Public Citizen maintains in a March 6 petition to FDA

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel